AGIO Agios Pharmaceuticals Inc.

62.1
-0.19  -0%
Previous Close 62.29
Open 62.15
Price To Book 5.28
Market Cap 3626355520
Shares 58,395,419
Volume 149,518
Short Ratio
Av. Daily Volume 468,867

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2H 2019.
AG-348 - Mitapivat
Thalassemia
FDA Approval announced July 20, 2018.
Ivosidenib
IDH1m Relapsed/Refractory AML - cancer
Phase 3 enrolment to be completed 2019.
AG-348 (ACTIVATE)
Pyruvate kinase deficiency
Phase 3 enrolment to be completed 2020.
AG-120 and VIDAZA - AGILE
Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer
Global Phase 3 study for AG-221 initiated October 2015. Continues to enroll as of January 2018.
Enasidenib (AG-221) - IDHENTIFY
Refractory Acute myeloid leukemia (AML) - cancer
Approval announced August 1, 2017.
IDHIFA (enasidenib) - AG-221
Advanced hematologic malignancies with an IDH2 mutation
Phase 3 top-line data due 1H 2019.
AG-120 Ivosidenib
IDH1 mutant positive cholangiocarcinoma - cancer
Phase 1 data at ASCO June 2018 noted CR rate was 24%.
AG-120 Ivosidenib
R/R Acute Myeloid Leukemia (AML)
Phase 1 updated data February 25, 2019 noted ORR of 78%, 57% CR rate, and 12-month Survival Rate of 82%.
Enasidenib or ivosidenib with VIDAZA
Frontline AML with IDH1 or IDH2 mutation
Phase 1 updated data at ASH December 2018. CR+CRi/CRp 80%.
Ivosidenib or enasidenib
Frontline AML with IDH1 or IDH2 mutation
Phase 1 dose escalation data due 1H 2019.
AG-270
Solid tumors
Phase 3 trial to be initiated YE 2019.
Vorasidenib (AG-881)
Glioma
PDUFA date under priority review June 21, 2019.
Ivosidenib
Frontline AML with IDH1 mutation
Phase 1 data due 1H 2019.
Ivosidenib and Vorasidenib (AG-881)
IDHm low-grade glioma

Latest News

  1. Why Is Agios Pharmaceuticals (AGIO) Up 13.2% Since Last Earnings Report?
  2. All You Need To Know About Agios Pharmaceuticals, Inc.’s (NASDAQ:AGIO) Financial Health
  3. Agios to Present at the Cowen 39th Annual Health Care Conference on Monday, March 11, 2019
  4. Agios Reports Updated Data from Phase 1 Study of Ivosidenib in Combination with Azacitidine Demonstrating Deep and Durable Responses in Newly Diagnosed IDH1 Mutant Acute Myeloid Leukemia (AML) Patients
  5. Analysis: Positioning to Benefit within Quest Diagnostics, Autodesk, Agios Pharmaceuticals, AMN Healthcare Services, Vistra Energy, and Helen of Troy — Research Highlights Growth, Revenue, and Consolidated Results
  6. Agios' Tibsovo Gets FDA Priority Review in First-Line Cancer
  7. Agios to Present at the Leerink Global Healthcare Conference on Thursday, February 28, 2019
  8. Edited Transcript of AGIO earnings conference call or presentation 14-Feb-19 1:00pm GMT
  9. Agios Announces FDA Acceptance of Supplemental New Drug Application for TIBSOVO® (ivosidenib) for the Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation Not Eligible for Standard Therapy
  10. Agios (AGIO) Q4 Earnings Beat, Tibsovo Sales Push Up Stock
  11. Agios Pharmaceuticals Inc (AGIO) Q4 2018 Earnings Conference Call Transcript
  12. Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates
  13. Agios Pharmaceuticals: 4Q Earnings Snapshot
  14. Agios Reports Fourth Quarter and Full Year 2018 Financial Results
  15. Agios ex-CEO joins GV as life sciences investment team's co-head
  16. See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.
  17. Agios Pharmaceuticals (AGIO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
  18. Have Insiders Been Selling Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares?
  19. 5 Biotech Stocks That Could Face M&A Next!